Jump to main content
Jump to site search


Positive Magnetic Resonance Angiography by Ultrafine Ferritin-based Iron Oxide Nanoparticles

Abstract

Iron oxide nanoparticles with good biocompatibility can serve as safe magnetic resonance imaging contrast agents. Herein, we report that ultrafine ferritin-based iron oxide (hematite/maghemite) nanoparticles synthesized by controlled biomimetic mineralization using genetically recombinant human H chain ferritin can be used as positive contrast agent in magnetic resonance angiography. The synthesized magnetoferritin with an averaged core size of 2.2±0.7 nm (hereafter named as M-HFn-2.2) shows r1 value of 0.86 mM-1s-1 and r2/r1 ratio of 25.1 at a 7 T magnetic field. Blood pool imaging on mice using the M-HFn-2.2 nanoparticles that injected through a tail vein by single injection at a dose of 0.54 mM Fe/kg mouse body weight, enabled detecting detailed vascular nets at 3 minutes post injection; the MR signal intensity continuously enhanced up to 2 hours post injection, which is much longer than the commercial magnevist (Gd-DTPA) contrast. Moreover, biodistribution examination indicates that organs of liver, spleen and kidney safely cleared the injected nanoparticles within one day after the injection, demonstrating no risk of iron overload in test mice. Therefore, this study sheds light on developing high-performance gadolinium free positive magnetic resonance contrast agents for biomedical applications.

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 Aug 2018, accepted on 20 Nov 2018 and first published on 28 Nov 2018


Article type: Paper
DOI: 10.1039/C8NR06812G
Citation: Nanoscale, 2018, Accepted Manuscript
  •   Request permissions

    Positive Magnetic Resonance Angiography by Ultrafine Ferritin-based Iron Oxide Nanoparticles

    Y. Cai, Y. Wang, H. Xu, C. Cao, R. Zhu, X. Tang, T. Zhang and Y. Pan, Nanoscale, 2018, Accepted Manuscript , DOI: 10.1039/C8NR06812G

Search articles by author

Spotlight

Advertisements